AWS is the trusted technology partner to the global healthcare and life sciences industry. For over 14 years, Amazon Web Services has been the world’s most comprehensive and broadly adopted cloud platform. Trusted by thousands of healthcare and life sciences customers around the world—including the fastest-growing startups, the largest enterprises, and the leading government agencies. AWS offers secure and compliant solutions to keep protected health information (PHI) private enabling the highly regulated healthcare and life sciences industry to increase the pace of innovation, unlock the potential of data, improve clinical and operational efficiency, and personalize the healthcare journey, improving the healthcare experience and ultimately patient outcomes.
Visiba Care is an innovative and scalable virtual care platform, enabling healthcare organizations to provide care with increased quality, efficiency and accessibility
Founded as a purpose-driven company in 2014, Visiba Care's mission is to empower healthcare providers and improve peoples lives. Visiba Care is the leading virtual care platform provider in Sweden and is advancing in other markets such as Norway, Finland and the UK. The customers vary in range, from smaller clinics to large healthcare organizations, both in the public and private sector.
APEIRON is a privately-held European biotech company based in Vienna, Austria, focused on the discovery and development of novel cancer immunotherapies and respiratory treatments.
Our company has a well balanced portfolio with one product on the market and several promising products from clinical to pre-clinical stages. As for the product on the market, APEIRON received EU marketing approval for APN311 (Dinutuximab beta, Qarziba®) in May 2017 for the treatment of pediatric neuroblastoma patients. We out-licensed Qarziba® globally to EUSA Pharma Ltd, for which it holds exclusive rights to this product.
APEIRON’s key projects and technologies are bolstered by a strong patent portfolio with broad territorial coverage. Our development expertise is validated through partnerships with leading global pharmaceutical companies and academic institutions.
Immunicom, Inc. creates novel immunotherapies designed to treat a variety of diseases using its breakthrough ImmunopheresisTM technology platform to improve patient access and affordability. The privately held medical technology company develops innovative, non-pharmaceutical approaches for treating cancer, autoimmune disorders, and inflammatory and renal diseases. Immunicom’s revolutionary blood-filtering Immunopheresis technology has the potential to effectively treat a wide variety of cancer types, including those that have not responded to other treatment strategies, with possibly fewer side effects. Immunicom’s lead product, the LW-02 column, has received U.S. FDA Breakthrough Device designation for stage IV metastatic cancer and European regulatory clearance (CE Mark certification) for use in adults with advanced, refractory, triple negative breast cancer (TNBC). Immunopheresis is currently being evaluated in several global oncology trials for multiple cancers. Immunicom is headquartered in San Diego, CA with operations in Philadelphia, PA, Houston, TX, and Krakow, Poland.
OUR VISION To create a world of bionic vision for those who have lost their sight.
OUR MISSION To provide best in class bionic vision restoration systems enabling the blind to regain greater autonomy and improved quality of daily living.
Pixium Vision, created in December 2011, is a bioelectronics and brain machine interface technology company specialized in neuromodulation application whose mission is to create a world of bionic vision for those who have lost their sight, enabling them to regain partial visual perception and greater autonomy.
Prima System features a miniaturized and totally wireless sub-retinal PRIMA implant, a pocket computer equipped with breakthrough algorithms, and a pair of glasses which captures the visual scene.
For the novel breakthrough Prima system, the exclusive transfer of the patented technology was granted by Stanford’s University to Pixium Vision to develop and industrialize the PRIMA bionic vision system.
Pixium Vision is currently conducting in France and in the United States, two feasibility clinical trials with PRIMA, for patients with severe vision loss due to retinal degeneration caused by the dry atrophic form of Age-related Macular Degeneration (AMD), for which there is no treatment available to date. https://www.pixium-vision.com/
10 minute showcases
Alertgy is a pioneer in 100% non-invasive continuous blood glucose monitoring technology. Through the use of its patent-pending radio frequency sensor Alertgy’s DeepGluco wearable device is able to accurately measure blood glucose in real time, up to 3 times per minute. Most importantly, using our proprietary AI algorithm, DeepGluco can provide invaluable, up to the minute life-saving alerts to the users and their designated HCPs. Unlike other CGMs, we eliminate interstitial lag as well as painful and uncomfortable side effects of patches, needles, and implants. The final DeepGluco form factor will be similar to modern smart watches, available to consumers following FDA approval.
Alio is a best in class wearable platform bringing together multiple metrics to drive insights across cardiovascular and pulmonary medicine through a single platform. Utilizing state-of-the-art advanced optics, Alio is able to non-invasively, deliver real-time clinical grademetrics such as Hemoglobin, Hematocrit, Temperature, Auscultation, Pulse Rate, Oxygen Saturation, Blood Pressure, Volumetric Blood Flow & Potassium. alio.ai
Arctoris is a research services company founded and headquartered in Oxford, UK. Arctoris developed and operates a fully automated drug discovery platform, conducting a broad range of assays across cell biology, molecular biology and biochemistry/ kinetics using advanced robotics. The unique technology platform enables Arctoris’ clients and partners to conduct their R&D – such as target validation, hit-to-lead, and lead optimisation – significantly faster, and with considerably improved data quality and depth. Arctoris offers both fee-for-service and risk-share agreements, and is trusted by biotech companies and academic centres in the US, UK, Germany, Australia, Korea, Hong Kong, and many other countries.
Genknowme is an innovative life sciences company dedicating itself to the transformation of cutting-edge research into epigenetic signatures that measure the impact of lifestyle on biological age. We provide a novel blood test to support healthcare professionals while they coach their patients into making healthy lifestyle changes.
InSphero is the pioneer of industrial-grade, 3D-cell-based assay solutions and scaffold-free 3D organ-on-a-chip technology. Through partnerships, InSphero supports pharmaceutical and biotechnology researchers in successful decision-making by accurately rebuilding the human physiology in vitro. Its robust and precisely engineered suite of 3D InSight™ human tissue platforms are used by major pharmaceutical companies worldwide to increase efficiency in drug discovery and safety testing. The company specializes in liver toxicology, metabolic diseases (e.g., T1 & T2 diabetes and NAFLD & NASH liver disease), and oncology (with a focus on immuno-oncology and PDX models). The scalable Akura™ technology underlying the company’s 3D InSight™ Discovery and Safety Platforms includes 96 and 384-well plate formats and the Akura™ Flow organ-on-a-chip system to drive efficient innovation throughout all phases of drug development. insphero.com
Novostia aims at improving the quality of life of people suffering from heart valve disease, especially children and young patients, providing them with a unique, durable, anticoagulant-free and silent heart valve prosthesis.
Heart valve diseases affect more than 100 million people worldwide. Every year hundreds of thousands of patients undergo a heart valve replacement. Available technologies entail serious constraints: lifelong anticoagulant medication or further replacements due to limited valve durability.
Thanks to a unique patented design and the use of a high-performance biocompatible polymer, Novostia eliminates all these constraints as well as clicking noises.
Sense Neuro Diagnostics is a medical device company developing non-invasive technology to enable rapid, comprehensive detection of stroke (by subtype) and traumatic brain injury to allow faster triage to proper care in a field enviornment, and continuous, real time monitoring of brain injury in hospital.
Volumina Medical is a Medtech start-up Company, born from the collaboration between plastic surgeons and biomaterial scientists.
Our vision is to become a leading player in the segment of regenerative medicine for making reconstructive surgery accessible to the majority of patients. Our mission is to help 1.8 million breast cancer patients per year to recover and retrieve the original shape and feel of their breast.
Our first product will enable to recreate a breast shape in one minimally invasive procedure, minimizing risks of complications, pain and costs.
Epios is a clinical-stage company providing personalized and precision management of neurological disorders using long-term brain monitoring and therapeutics.
Our first product is a subscalp, minimally invasive, 24/7, insertable device for long-term monitoring of brain’s Electroencephalography (EEG) signals. We are pioneering a new modality in brain monitoring: Subscalp EEG offers long-term, continuous and reliable recording of neural activity targeted first for people with epilepsy.
Our company started with Biel, a child born with low vision (LV). LV is a condition in which vision is permanently limited and cannot be corrected by standard glasses, contact lenses, medicine or conventional surgery. There are 217 million people worldwide with LV. Mobility problems are its most disabling effect, causing falls, injuries, dependence and social isolation. We are a team of businesspeople, doctors, technologists and optometrists creating intelligent glasses that adapt reality to the remaining vision of people with LV, improving their mobility and personal autonomy. Our device uses AI and robotics to detect and evaluate obstacles, traffic lights, steps and other elements relevant to patient mobility, and mixed reality to indicate those elements so that patients can perceive them with their remaining vision. The device includes image zoom, lighting adaption and other convenient image enhancements to create a complete solution for the LV.
Healium's mission is to advance therapy of atrial fibrillation therapy, the most common cardiac arrhythmia and a leading cause of ischemic stroke. The company develops ultrasound ablation technology that allows rapid, no-contact therapy, integrated with real-time lesion monitoring in a single catheter. This stands in sharp contrast to existing solutions that require tissue contact and provide no lesion imaging leading to poor 60% clinical outcome. The company has raised $3.25M to date, has compelling results from animal studies with strong support from key opinion leaders in the field. Our solution is based on proprietary ultrasound technology that allows contactless circumferential lesion with real-time lesion imaging with a single catheter. Eliminating the need for tissue contact significantly simplifies the procedure and eliminates the need for extensive experience associated with catheter steering and manipulation. Providing real-time lesion detection capabilities will eliminate the current guess work associated with lesion formation as tissue thickness and properties are visualized and automatically drive energy level used to effectively ablate the tissue.
LS CancerDiag has its origins at the University of Helsinki and has developed DIAGMMR®, a unique predictive diagnostic test to detect Lynch syndrome, the most common inherited predisposition to cancer. We provide easily interpretable and highly accurate results even before cancers develop, enabling preventive and personalized care.
MOWOOT is a growth stage medical device company targeting intestinal transit disorders with a purely physical, non-drug, non-invasive solution.
The medical device MOWOOT II System provides a novel Intermittent Colonic Exo-peristalsis (I.C.E.) treatment for intestinal transit disorders. The I.C.E. Therapy is purely physical, physiological, non-invasive and non pharmacological & works with pneumatic technology: four actuators with real-time pressure-sensors produce a wave-like exo-peristaltic effect that promotes intestinal transit and colonic secretion.
The MOWOOT II System is a CE certified class IIa medical device, IP protected, on the market in Spain, Germany, UK and Netherlands and clinically proven.
Most current sales are already reimbursed by private halthcare insurances and public healthcare reimbursement is expected in Germany in 2021.
Munevo helps people with innovative technology solutions. Munevo DRIVE is the first platform solution for people with disabilities that uses smart glass technology. It supports people with spinal cord injuries and muscular diseases to be independent. By combining user-centric design and adapting technology Munevo creates solutions to scale.
Pilloxa promotes patients health through the use of smart digital technology.
Our digital platform for patient-centric support of adherence to treatment allows medication follow up throughout the entire therapeutic journey, from clinical trials to daily practice.
Trusted by global pharmaceutical companies and world-renowned hospitals, Pilloxa's offerings are now being used in several therapeutic areas where adherence is of utmost importance. We are excited to drive development in this field and look forward to creating a difference for the millions of patients that medicate daily.
Our proprietary sensor- and medical AI-technology is the results of 10 years clinical research. Clinical proof-of-concept has been shown in more than 3.000 stratified gait analyses. Additional market opportunities include MS, combination pharmaceutical products. We are currently closing our Series A round. Last tickets are available.
We develop a novel stimulator for the peripheral nervous system. Its novelty is that it can be implanted inside peripheral nerves, providing more focused stimulation, with respect to other available technologies. Moreover, the stimulation can be modulated according to the readout of wearables or implantable sensors.
Oral implants are now widely used in the clinic. However, there remains risks of failure (currently around 15%), which are highly detrimental for both patients (aesthetic issues, nutrition troubles, loss of confidence, etc.) and surgeons (in terms of cost, reputation and law suits). WaveImplant is developing ImplantUS, an innovative and patented ultrasound medical device aiming at measuring dental implant stability. ImplantUS will help practitioners optimize their surgical procedures in dental implantology and will reduce the dental implant failure rate as early as 2023.
WaveImplant was created in May 2019 by Guillaume Haïat (VP Scientific Affairs) and Pascal Breton (CEO). Guillaume Haïat, inventor of the technology, has twenty years of experience in academic and industrial research. Pascal Breton is a "serial entrepreneur" with an international career of thirty years in the Health and Life Sciences industry. The management team was completed in late 2020 with the arrival of Thierry Toubiana, deputy general manager, who has 9 years of experience as general manager France of BioHorizon, 5th implant manufacturer worldwide.
The technology of ImplantUS is based on quantitative ultrasound. It has been validated in vitro, in silico and in vivo (rabbits and sheep). We are now working on the clinical trials. This approach constitutes a technological breakthrough and presents strong competitive advantages as it allows a more precise and reliable measurement of implant stability than any other technology currently available on the market. The technology is protected by two families of patents and patent applications (2009 and 2018). The commercialization of ImplantUS will begin 2023. It will be marketed directly by WaveImplant in France, and under license agreements with one or more heavyweights of the sector abroad. WaveImplant will retain control of ImplantUS production and know-how through its subcontractors.